<i>Candida</i>
            Bloodstream Infections: Comparison of Species Distributions and Antifungal Resistance Patterns in Community-Onset and Nosocomial Isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009

Pfaller, Michael A.; Moet, Gary J.; Messer, S. A.; Jones, Ronald N.; Castanheira, Mariana

doi:10.1128/aac.01079-10

Cited by 224 publications

(176 citation statements)

References 49 publications

Supporting

Mentioning

166

Contrasting

Unclassified

Order By: Relevance

“…krusei represented (6.9%) of isolated Candida species in our study and this finding was nearly similar to the rate (13%) reported by other studies [9,11]. Certain systemic factors like serum ferritin had increase the predisposition for oral Candida colonization due to their effects in immune system [3].…”

Section: Discussionsupporting

confidence: 81%

Antifungal Susceptibility of Oral Candida Species Isolated from Patients with Thalassemia Major

Kasem

Shokry

Mohamed

et al. 2017

JBMOA

View full text Add to dashboard Cite

Background: Invasive fungal infections are the primary cause of morbidity and mortality in patients with thalassemias. This high mortality rate stems, in part, from the prevalence of resistance to antifungal agents. Candida species remain the most common cause of invasive fungal infection in patients with thalassemia. Nevertheless, other Candida species become increasingly spreading and need to be identified to a species level.Objectives: The objectives of the study were to estimate the prevalence of Candida infection among Thalassemia major patients compared to healthy controls and to identify the resistance patterns among the recovered species.Methods: A total of 60 oral samples were collected from two groups: Group I: 40 oral swabs were collected from patients clinically diagnosed with thalassemia major from the out-patient clinics of Pediatric department in Ain Shams University Hospital. Group II: 20 oral swabs were collected from healthy subjects matched in age and sex with the patients' group. The swabs were cultured onto both CHROM and Sabaroud's agar media. The recovered colonies on Sabaroud's agar were identified using Gram stain and Germ tube test while the colonies on CHROM agar were self-identified through color produced according to manufacturer instructions. For all identified colonies API 20 C AUX was used as a confirmatory test. Antifungal Susceptibility testing using Fluconazole (25μg).Voriconazole (1μg).Nystatin (100 units) was used to identify the resistance strains.Results: C. albicans, were isolated from 69.2% of cases while 30.8% were non C. albicans. (23% C. tropicalis and 7.8% C. krusei). Susceptibility testing for all identified colonies revealed that (13.8%) of all isolates were resistant to fluoconazole, (17.3%) to voriconazole and (89.7%) to nystatin. Conclusion:The use of CHROM agar media offers multiple advantages without increasing costs in comparison to other procedures. CHROM agar media have equal or greater sensitivity of detection, superior detection of mixed cultures as a result of better visualization of different species, and enable shorter times to report results. Antifungal susceptibility tests are now required to optimize antifungal treatment to avoid emergence of new resistant strains.

show abstract

Section: Discussionsupporting

confidence: 81%

Antifungal Susceptibility of Oral Candida Species Isolated from Patients with Thalassemia Major

Kasem

Shokry

Mohamed

et al. 2017

JBMOA

View full text Add to dashboard Cite

show abstract

“…were cultured from either blood or intravascular devices (IVDs), such as central venous catheter tips, from patients meeting the criteria for nosocomial bloodstream infection due to Candida spp. [11]. Only a single strain of Candida was collected in each patient, and this was considered to be representative of an infectious episode if one or more blood or IVD cultures yielded growth of the same Candida spp.…”

Section: Methodsmentioning

confidence: 99%

Candidaemia in a tertiary care academic hospital in Italy. The impact of C. parapsilosis complex on the species distribution and antifungal susceptibility

Ghezzi

Brunetti

Visconti

et al. 2017

Journal of Medical Microbiology

View full text Add to dashboard Cite

Purpose. To analyse the species distribution and the susceptibility profiles to the major antifungal agents of Candida isolated from bloodstream infections (BSIs) in both intensive care units (ICUs) and non-ICU wards in a tertiary care hospital in Italy from 2010 until 2015.Methodology. Episodes of Candida BSI were recorded in a retrospective observational cohort study. Yeasts were isolated from both blood and intravascuIar devices (IVDs) and their susceptibility to antifungal drugs was tested using the microdilution method.Results. 514 Candida BSIs were evidenced and 19 % of these episodes were associated with the presence of an IVD. The trend of the general incidence increased significantly throughout the study period, ranging from 1.42 to 3.63 (mean 2.52) episodes/1000 admissions. The incidence of Candida BSIs and IVD-associated candidaemia was significantly higher in ICUs relative to the other wards. The most frequently isolated species were C. albicans and C. parapsilosis complex, with the latter presenting a significant increased trend of isolation. C. parapsilosis complex was most frequently involved in IVD-related candidaemia, coinfections and late recurrent infections. Furthermore, the MIC 50 s of C. parapsilosis complex were significantly enhanced for echinocandins compared to the MIC 50 s for the same drugs and the other yeasts, while the MIC 50 s of C. albicans for amphotericin B showed a significant increase during the study period, ranging from 0.1 to 0.5 µg ml À1 . Conclusions.A progressively enhanced incidence of Candida BSIs, a relatively high impact of C. parapsilosis complex and changes in the susceptibility profiles of the isolated yeasts were evidenced during the observation period.

show abstract

“…Echinocandins also are the preferred empiric therapy for suspected candidiasis in nonneutropenic patients in the intensive care unit (Pappas et al, 2009; Pappas et al, 2016). Overall, current frequency of echinocandin resistance remains relatively low (< 1%) with Candida albicans and most other Candida species except Candida glabrata (Castanheira et al, 2010; Pfaller et al, 2011; Pfaller et al, 2013). However, widespread echinocandin usage has been accompanied by reports of emerging multidrug resistance among clinical Candida isolates (Alexander et al, 2013; Fekkar et al, 2014), as well as epidemiological shifts with increased proportion of less susceptible Candida species (Lortholary et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

CD101: a novel long‐acting echinocandin

Zhao

Perez

Jiménez‐Ortigosa

et al. 2016

Cellular Microbiology

View full text Add to dashboard Cite

SummaryCD101 is a novel echinocandin drug being developed to treat severe fungal infections including invasive candidiasis. We have performed a series of studies to evaluate the antifungal properties of CD101 against both echinocandin‐susceptible and ‐resistant Candida strains. Antifungal susceptibility testing performed on a collection of 95 Candida strains including 30 caspofungin‐resistant isolates containing fks mutations demonstrated comparable antifungal potency of CD101 relative to micafungin (MCF) across different Candida species. Comparable kinetic inhibition of glucan synthase activity was also observed for CD101 and MCF on both wild‐type (WT) and resistant fks mutant Candida strains. Similarly, both drugs yielded nearly identical values for a mutant prevention concentration. In a murine model of invasive candidiasis, CD101 displayed better or at least comparable efficacy relative to MCF in treating WT or fks mutant Candida albicans. An exceptional long‐lived pharmacokinetic profile was observed in mice following a single dose of CD101. Collectively, CD101 has great potential not only in treating invasive Candida infections but also in preventing emergence of resistance to currently approved echinocandin drugs.

show abstract

Candida Bloodstream Infections: Comparison of Species Distributions and Antifungal Resistance Patterns in Community-Onset and Nosocomial Isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009

Cited by 224 publications

References 49 publications

Antifungal Susceptibility of Oral Candida Species Isolated from Patients with Thalassemia Major

Antifungal Susceptibility of Oral Candida Species Isolated from Patients with Thalassemia Major

Candidaemia in a tertiary care academic hospital in Italy. The impact of C. parapsilosis complex on the species distribution and antifungal susceptibility

CD101: a novel long‐acting echinocandin

Contact Info

Product

Resources

About